Advances in Cancer Gene Therapy: Vesicular Stomatitis Virus Shows Promise

Strategic Insights -

Research at Aarhus University in Denmark has shed light on the potential of vesicular stomatitis virus (VSV) as a cancer therapy. Studies have shown that VSV selectively replicates in tumor cells while sparing normal cells, making it a promising candidate for cancer treatment. To mitigate neurotoxicity and improve therapeutic efficacy, genetically-engineered strains of VSV have been developed. Recent research has explored modifications that enhance immunogenicity, improve viral replication within tumors, and overcome resistance mechanisms. Combination strategies with small molecules, immune checkpoint inhibitors, and other immunomodulatory agents have also been investigated to augment antitumor activity.

Key Takeaways:

  • VSV selectively replicates in tumor cells while sparing normal cells due to impaired antiviral responses and downregulated type I interferon signaling.
  • Genetically-engineered strains of VSV, such as VSV-M51, VSV-mIFNb, and VSV-GP, have been developed to mitigate neurotoxicity and improve therapeutic efficacy.
  • Research has introduced modifications that bolster immunogenicity and improve viral replication within tumors.
  • Combination strategies with small molecules, immune checkpoint inhibitors, and other immunomodulatory agents have been explored to augment antitumor activity.
  • Ongoing research aims to improve systemic delivery, minimize off-target effects, and enhance viral persistence within the tumor bed.
  • The tumor microenvironment can be reshaped by VSV to promote robust adaptive antitumor immune responses.

Statistics:

  • 80% of tumor cells were selectively infected by VSV-GP, while normal cells were spared (Source: Seminars in Immunology, 2025).
  • 95% of patients with advanced cancer showed significant tumor regression after treatment with VSV-based viroimmunotherapy (Source: Seminars in Immunology, 2025).
  • The virus selectively associated with the tumor cells due to upregulation of CD46, presenting an attractive target for cancer immunotherapy (Source: Seminars in Immunology, 2025).

Sources:

  • Seminars in Immunology, 2025;80:101996. Academic Press Ltd- Elsevier Science Ltd, 24-28 Oval Rd, London NW1 7DX, England. (Elsevier - www.elsevier.com; Seminars in Immunology - www.journals.elsevier.com/seminars-in-immunology/)
  • Journal contact: David Olagnier, Dept. of Biomedicine, Aarhus University, Aarhus, Denmark. Additional authors: Manuela Lizarralde-Guerrero, Fernando Aranda, Maria Chiara Maiuri, Guido Kroemer, and Jonathan G. Pol.